Actemra (tocilizumab), a biologic drug being developed to treat rheumatoid arthritis by Roche Pharmaceuticals, has produced successful results in the third Phase III trial conducted. Actemra is a first-in-class humanized anti-interleukin-6 receptor monoclonal antibody. There were 498 patients in the trial known as Actemra RADIATE (Rheumatoid Arthritis Study in Anti-TNF Failures). The RADIATE trial studied Actemra in moderate to severe rheumatoid arthritis patients who failed to respond to anti-tumor necrosis factor treatments (anti-TNF drugs) e.g., Enbrel, Remicade, and Humira.
No comments:
Post a Comment